Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features

[Purpose] CAR therapy targeting BCMA is under investigation as treatment for multiple myeloma. However, given the lack of plateau in most studies, pursuing more effective alternatives is imperative. We present the preclinical and clinical validation of a new optimized anti-BCMA CAR (CARTemis-1). In...

Descripción completa

Detalles Bibliográficos
Autores: Sierro-Martínez, Belén, Escamilla-Gómez, Virginia, Pérez-Ortega, Laura, Guijarro-Albaladejo, Beatriz, Hernández-Díaz, Paola, Rosa Garrido, María de la, Lara Chica, Maribel, Rodríguez-Gil, Alfonso, Reguera-Ortega, Juan Luis, Sanoja-Flores, Luzalba, Arribas-Arribas, Blanca, Montiel Aguilera, Miguel Ángel, Carmona Sánchez, Gloria, Robles, María José, Caballero Velázquez, Teresa, Briones, Javier, Einsele, Hermann, Hudecek, Michael, Pérez-Simón, José A., García-Guerrero, Estefanía
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/390728
Acceso en línea:http://hdl.handle.net/10261/390728
https://api.elsevier.com/content/abstract/scopus_id/85202174277
Access Level:acceso abierto
Palabra clave:CAR-T
Immunophenotype monitoring
Manufacturing procedure
Multiple myeloma
Anti-BCMA
Descripción
Sumario:[Purpose] CAR therapy targeting BCMA is under investigation as treatment for multiple myeloma. However, given the lack of plateau in most studies, pursuing more effective alternatives is imperative. We present the preclinical and clinical validation of a new optimized anti-BCMA CAR (CARTemis-1). In addition, we explored how the manufacturing process could impact CAR-T cell product quality and fitness.

Similares en LA Referencia